author-photo

Jenny King

The Royal Marsden NHS Foundation Trust

2

Papers

15

Citations

Citation Trend

Filter By

Papers (2) Sort By

JournalConferenceOthers

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

2020 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (6)
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (9)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号